Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 May 31;14(5):e25537.
doi: 10.7759/cureus.25537. eCollection 2022 May.

A Systematic Review of the Efficacy and Safety of Fecal Microbiota Transplantation in the Treatment of Hepatic Encephalopathy and Clostridioides difficile Infection in Patients With Cirrhosis

Affiliations
Review

A Systematic Review of the Efficacy and Safety of Fecal Microbiota Transplantation in the Treatment of Hepatic Encephalopathy and Clostridioides difficile Infection in Patients With Cirrhosis

Kyaw Min Tun et al. Cureus. .

Abstract

The microbiome of the human gut and liver coexists by influencing the health and disease state of each system. Fecal microbiota transplantation (FMT) has recently emerged as a potential treatment for conditions associated with cirrhosis, such as hepatic encephalopathy and recurrent/refractory Clostridioides difficile infection (rCDI). We have conducted a systematic review of the safety and efficacy of FMT in treating hepatic encephalopathy and rCDI. A literature search was performed using variations of the keywords "fecal microbiota transplant" and "cirrhosis" on PubMed/MEDLINE from inception to October 3, 2021. The resulting 116 articles were independently reviewed by two authors. Eight qualifying studies were included in the systematic review. A total of 127 cirrhotic patients received FMT. Hepatic encephalopathy was evaluated by cognitive tests, such as the Psychometric Hepatic Encephalopathy Score (PHES) and EncephalApp Stroop test. Not only was there an improvement in the cognitive performance in the FMT cohort, but the improvement was also maintained throughout long-term follow-up. In the treatment of rCDI, the FMT success rate is similar between cirrhotic patients and the general population, although more than one dose may be needed in the former. The rate of serious adverse events and adverse events in the cirrhotic cohort was slightly higher than that in the general population but was low overall. We found evidence that supports the therapeutic potential and safety profile of FMT to treat hepatic encephalopathy and rCDI in cirrhotic patients. Further research will be beneficial to better understand the role of FMT in cirrhosis.

Keywords: adverse outcomes; cirrhosis; clostridioides difficile infection; fecal microbiota transplantation; hepatic encephalopathy.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) diagram of the study selection and data extraction process
FMT: Fecal microbiota transplantation.

Similar articles

Cited by

References

    1. Fecal microbiota transplant in cirrhosis reduces gut microbial antibiotic resistance genes: analysis of two trials. Bajaj JS, Shamsaddini A, Fagan A, et al. Hepatol Commun. 2021;5:258–271. - PMC - PubMed
    1. Role of gut microbiota in liver disease. Albhaisi SA, Bajaj JS, Sanyal AJ. Am J Physiol Gastrointest Liver Physiol. 2020;318:0–98. - PubMed
    1. Gut-liver axis, cirrhosis and portal hypertension: the chicken and the egg. Arab JP, Martin-Mateos RM, Shah VH. Hepatol Int. 2018;12:24–33. - PMC - PubMed
    1. Fecal microbiota transplantation in hepatic encephalopathy: a systematic review. Madsen M, Kimer N, Bendtsen F, Petersen AM. Scand J Gastroenterol. 2021;56:560–569. - PubMed
    1. Intestinal microbiota in liver disease. Haque TR, Barritt AS 4th. Best Pract Res Clin Gastroenterol. 2016;30:133–142. - PubMed

LinkOut - more resources